Shigella flexneri 2a InvaplexAR / U.S. Army Medical Research and Development Command - LARVOL DELTA

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) (clinicaltrials.gov) - P1; N=38; Completed; Sponsor: U.S. Army Medical Research and Development Command; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Trial primary completion date: Mar 2017 ➔ Mar 2018

Trial primary completion date • Biosimilar • Immunology

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: Dec 2019 ➔ Jun 2020

Clinical • Trial completion date

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: U.S. Army Medical Research and Development Command; Trial completion date: Mar 2020 ➔ Dec 2019

Clinical • Trial completion date

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: U.S. Army Medical Research and Materiel Command; Trial primary completion date: Mar 2019 ➔ Jul 2019

Clinical • Trial primary completion date